{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:50:22Z","timestamp":1790740222094,"version":"4.1.0"},"reference-count":124,"publisher":"Oxford University Press (OUP)","issue":"suppl_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the past, most antifungal therapy dosing recommendations for invasive candidiasis followed a \u2018one-size fits all\u2019 approach with recommendations for lowering maintenance dosages for some antifungals in the setting of renal or hepatic impairment. A growing body of pharmacokinetic\/pharmacodynamic research, however now points to a widespread \u2018silent epidemic\u2019 of antifungal underdosing for invasive candidiasis, especially among critically ill patients or special populations who have altered volume of distribution, protein binding and drug clearance. In this review, we explore how current adult dosing recommendations for antifungal therapy in invasive candidiasis have evolved, and special populations where new approaches to dose optimization or therapeutic drug monitoring may be needed, especially in light of increasing antifungal resistance among Candida spp.<\/jats:p>","DOI":"10.1093\/jac\/dkx447","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T12:13:30Z","timestamp":1510661610000},"page":"i33-i43","source":"Crossref","is-referenced-by-count":39,"title":["Overview of antifungal dosing in invasive candidiasis"],"prefix":"10.1093","volume":"73","author":[{"given":"Federico","family":"Pea","sequence":"first","affiliation":[{"name":"Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital of Udine, ASUIUD, Udine, Italy"},{"name":"Department of Medicine, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell E","family":"Lewis","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, S. Orsola-Malpighi Hospital; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"2019071816003186200_dkx447-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2011.07.013","article-title":"Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review","volume":"39","author":"Sinnollareddy","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2019071816003186200_dkx447-B2","doi-asserted-by":"crossref","first-page":"33.","DOI":"10.1186\/s13054-015-0758-3","article-title":"Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients study","volume":"19","author":"Sinnollareddy","year":"2015","journal-title":"Crit Care"},{"key":"2019071816003186200_dkx447-B3","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1128\/AAC.00116-08","article-title":"Association of fluconazole pharmacodynamics with mortality in patients with candidemia","volume":"52","author":"Baddley","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B4","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1097\/CCM.0b013e31818b3477","article-title":"Treatment-related risk factors for hospital mortality in Candida bloodstream infections","volume":"36","author":"Labelle","year":"2008","journal-title":"Crit Care Med"},{"key":"2019071816003186200_dkx447-B5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/AAC.00474-06","article-title":"Association of fluconazole area under the concentration-time curve\/MIC and dose\/MIC ratios with mortality in nonneutropenic patients with candidemia","volume":"51","author":"Pai","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/jac\/dkw352","article-title":"Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation","volume":"72","author":"Jullien","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019071816003186200_dkx447-B7","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.2016.14655","article-title":"Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial","volume":"316","author":"Timsit","year":"2016","journal-title":"JAMA"},{"key":"2019071816003186200_dkx447-B8","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMra1315399","article-title":"Invasive candidiasis","volume":"373","author":"Kullberg","year":"2015","journal-title":"N Engl J Med"},{"key":"2019071816003186200_dkx447-B9","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1128\/AAC.00019-12","article-title":"Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia","volume":"56","author":"Shah","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B10","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/QCO.0000000000000111","article-title":"Echinocandin resistance: an emerging clinical problem?","volume":"27","author":"Arendrup","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"2019071816003186200_dkx447-B11","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1128\/AAC.01763-15","article-title":"Posttreatment antifungal resistance among colonizing Candida isolates in candidemia patients: results from a systematic multicenter study","volume":"60","author":"Jensen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B12","doi-asserted-by":"crossref","first-page":"e01229","DOI":"10.1128\/AAC.01229-16","article-title":"Echinocandin resistance in Candida species isolates from liver transplant recipients","volume":"61","author":"Prigent","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/cid\/ciw696","article-title":"Emergence of Candida auris: an international call to arms","volume":"64","author":"Clancy","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2019071816003186200_dkx447-B14","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/cid\/cit140","article-title":"Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida","volume":"56","author":"Ostrosky-Zeichner","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2019071816003186200_dkx447-B15","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"key":"2019071816003186200_dkx447-B16","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/CMR.11.2.382","article-title":"Clinical, cellular, and molecular factors that contribute to antifungal drug resistance","volume":"11","author":"White","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"2019071816003186200_dkx447-B17","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/clinids\/24.5.776","article-title":"Antifungal susceptibility testing: technical advances and potential clinical applications","volume":"24","author":"Pfaller","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2019071816003186200_dkx447-B18","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard M27-A","author":"Clinical Laboratory and Standards Institute","year":"1997"},{"key":"2019071816003186200_dkx447-B19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/clinids\/24.2.235","article-title":"Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards","volume":"24","author":"Rex","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2019071816003186200_dkx447-B20","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/AAC.43.9.2116","article-title":"Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model","volume":"43","author":"Andes","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B21","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1128\/AAC.42.5.1105","article-title":"Pharmacodynamics of fluconazole in a murine model of systemic candidiasis","volume":"42","author":"Louie","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B22","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/AAC.01354-13","article-title":"Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B23","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1128\/AAC.47.10.3165-3169.2003","article-title":"In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.48.1.137-142.2004","article-title":"Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis","volume":"48","author":"Andes","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B25","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1128\/AAC.01305-05","article-title":"In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B26","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/CMR.14.4.643-658.2001","article-title":"Antifungal susceptibility testing: practical aspects and current challenges","volume":"14","author":"Rex","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"2019071816003186200_dkx447-B27","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.01411-08","article-title":"Association of fluconazole pharmacodynamics with mortality in patients with candidemia","volume":"53","author":"Arendrup","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B28","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1128\/AAC.44.10.2715-2718.2000","article-title":"Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole","volume":"44","author":"Lee","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B29","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1128\/AAC.00296-07","article-title":"Correlation of the MIC and dose\/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia","volume":"51","author":"Rodriguez-Tudela","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B30","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s10096-004-1128-2","article-title":"Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection","volume":"23","author":"Takakura","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2019071816003186200_dkx447-B31","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1128\/AAC.49.8.3171-3177.2005","article-title":"Fluconazole MIC and the fluconazole dose\/MIC ratio correlate with therapeutic response among patients with candidemia","volume":"49","author":"Clancy","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B32","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2165\/00003495-199550040-00007","article-title":"Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients","volume":"50","author":"Goa","year":"1995","journal-title":"Drugs"},{"key":"2019071816003186200_dkx447-B33","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1128\/AAC.00081-09","article-title":"Data mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility Testing","volume":"53","author":"Cuesta","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.drup.2010.09.002","article-title":"Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods","volume":"13","author":"Pfaller","year":"2010","journal-title":"Drug Resist Updat"},{"key":"2019071816003186200_dkx447-B35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1039\/C3NP70070D","article-title":"Discovery and development of first in class antifungal caspofungin (CANCIDAS(R)) \u2013 a case study","volume":"31","author":"Balkovec","year":"2014","journal-title":"Nat Prod Rep"},{"key":"2019071816003186200_dkx447-B36","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.46.3.739-745.2002","article-title":"Single- and multiple-dose pharmacokinetics of caspofungin in healthy men","volume":"46","author":"Stone","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B37","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1128\/AAC.47.4.1187-1192.2003","article-title":"In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B38","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","author":"Andes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B39","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AAC.01061-07","article-title":"In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model","volume":"52","author":"Andes","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B40","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1128\/AAC.00478-08","article-title":"In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model","volume":"52","author":"Andes","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B41","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1128\/AAC.00507-06","article-title":"Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis","volume":"50","author":"Gumbo","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B42","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1128\/AAC.49.12.5058-5068.2005","article-title":"Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity","volume":"49","author":"Louie","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B43","doi-asserted-by":"crossref","first-page":"S643","DOI":"10.1093\/cid\/civ817","article-title":"Intermittent dosing of micafungin is effective for treatment of experimental disseminated candidiasis in persistently neutropenic rabbits","volume":"61","author":"Petraitiene","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019071816003186200_dkx447-B44","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/JCM.00566-08","article-title":"Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints","volume":"46","author":"Pfaller","year":"2008","journal-title":"J Clin Microbiol"},{"key":"2019071816003186200_dkx447-B45","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1128\/AAC.01337-06","article-title":"Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B46","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2011.01.004","article-title":"Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria","volume":"14","author":"Pfaller","year":"2011","journal-title":"Drug Resist Updat"},{"key":"2019071816003186200_dkx447-B47","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1128\/AAC.01102-12","article-title":"Optimizing echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations","volume":"56","author":"Lepak","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B48","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.01430-10","article-title":"Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia","volume":"55","author":"Andes","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B49","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1177\/0091270005279580","article-title":"Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction","volume":"45","author":"Hebert","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"2019071816003186200_dkx447-B50","doi-asserted-by":"crossref","first-page":"S635","DOI":"10.1093\/cid\/civ715","article-title":"Single or 2-dose micafungin regimen for treatment of invasive candidiasis: therapia sterilisans magna!","volume":"61","author":"Gumbo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019071816003186200_dkx447-B51","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1128\/AAC.02124-15","article-title":"Efficacy of extended-interval dosing of micafungin evaluated using a pharmacokinetic\/pharmacodynamic study with humanized doses in mice","volume":"60","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B52","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.1128\/AAC.01057-13","article-title":"Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization","volume":"57","author":"Andes","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B53","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1086\/598933","article-title":"A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis","volume":"48","author":"Betts","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"2019071816003186200_dkx447-B54","doi-asserted-by":"crossref","first-page":"i44","DOI":"10.1093\/jac\/dkx448","article-title":"We can do better: a fresh look at echinocandin dosing","volume":"73","author":"Bader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019071816003186200_dkx447-B55","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ1194","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019071816003186200_dkx447-B56","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1128\/AAC.50.2.674-684.2006","article-title":"Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B57","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1128\/AAC.45.3.922-926.2001","article-title":"Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model","volume":"45","author":"Andes","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B58","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1128\/AAC.50.4.1287-1292.2006","article-title":"Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome","volume":"50","author":"Park","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B59","doi-asserted-by":"crossref","first-page":"a019653.","DOI":"10.1101\/cshperspect.a019653","article-title":"Antifungal pharmacokinetics and pharmacodynamics","volume":"5","author":"Lepak","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2019071816003186200_dkx447-B60","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.50.3.935-942.2006","article-title":"Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases","volume":"50","author":"Hong","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B61","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1128\/AAC.44.4.938-942.2000","article-title":"In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model","volume":"44","author":"Andes","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B62","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1128\/AAC.00488-07","article-title":"Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing","volume":"51","author":"Hope","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B63","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/jac\/dkl550","article-title":"Flucytosine therapeutic monitoring: 15 years experience from the UK","volume":"59","author":"Pasqualotto","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2019071816003186200_dkx447-B64","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijantimicag.2013.06.005","article-title":"Candidaemia in the non-neutropenic patient: a critique of the guidelines","volume":"42","author":"Deshpande","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2019071816003186200_dkx447-B65","first-page":"1050","article-title":"Augmented renal clearance in critical illness: \u201cthe elephant in the ICU\u201d?","volume":"81","author":"Baptista","year":"2015","journal-title":"Minerva Anestesiol"},{"key":"2019071816003186200_dkx447-B66","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijantimicag.2009.12.021","article-title":"Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study","volume":"35","author":"Myrianthefs","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2019071816003186200_dkx447-B67","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2019071816003186200_dkx447-B68","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/phar.1400","article-title":"CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?","volume":"34","author":"Owusu Obeng","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2019071816003186200_dkx447-B69","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/AAC.01558-13","article-title":"A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid","volume":"58","author":"Wiederhold","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B70","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bcpt.12530","article-title":"Variability of voriconazole trough levels in haematological patients: influence of comedications with cytochrome P450(CYP) inhibitors and\/or with CYP inhibitors plus CYP inducers","volume":"118","author":"Cojutti","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2019071816003186200_dkx447-B71","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijantimicag.2014.05.019","article-title":"Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity","volume":"44","author":"Dolton","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2019071816003186200_dkx447-B72","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"2019071816003186200_dkx447-B73","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy","author":"Moriyama","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"2019071816003186200_dkx447-B74","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1128\/AAC.00054-16","article-title":"Drug-drug interaction associated with mold-active triazoles among hospitalized patients","volume":"60","author":"Andes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B75","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1592\/phco.30.8.842","article-title":"Management of drug and food interactions with azole antifungal agents in transplant recipients","volume":"30","author":"Dodds-Ashley","year":"2010","journal-title":"Pharmacotherapy"},{"key":"2019071816003186200_dkx447-B76","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2019071816003186200_dkx447-B77","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/jop.1998.14.459","article-title":"Comparison of fluconazole pharmacokinetics in serum, aqueous humor, vitreous humor, and cerebrospinal fluid following a single dose and at steady state","volume":"14","author":"Mian","year":"1998","journal-title":"J Ocul Pharmacol Ther"},{"key":"2019071816003186200_dkx447-B78","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/jac\/dkp306","article-title":"Intraocular penetration of voriconazole and caspofungin in a patient with fungal endophthalmitis","volume":"64","author":"Spriet","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2019071816003186200_dkx447-B79","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/jac\/dku169","article-title":"Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis","volume":"69","author":"Pea","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2019071816003186200_dkx447-B80","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1093\/jac\/dku313","article-title":"Pharmacokinetics of caspofungin in ICU patients","volume":"69","author":"Muilwijk","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2019071816003186200_dkx447-B81","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1128\/AAC.01607-13","article-title":"Low but sufficient anidulafungin exposure in critically ill patients","volume":"58","author":"van Wanrooy","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B82","doi-asserted-by":"crossref","first-page":"e01894","DOI":"10.1128\/AAC.01894-16","article-title":"Pharmacokinetics of anidulafungin in critically ill intensive care unit patients with suspected or proven invasive fungal infections","volume":"61","author":"Bruggemann","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B83","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1128\/AAC.00623-15","article-title":"Altered micafungin pharmacokinetics in intensive care unit patients","volume":"59","author":"Lempers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B84","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1086\/431761","article-title":"Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis","volume":"41","author":"Gauthier","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2019071816003186200_dkx447-B85","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijantimicag.2017.02.024","article-title":"Low penetration of caspofungin into cerebrospinal fluid following intravenous administration of standard doses","volume":"50","author":"Strenger","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2019071816003186200_dkx447-B86","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1128\/AAC.46.12.3719-3723.2002","article-title":"Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model","volume":"46","author":"Goldblum","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B87","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system","volume":"182","author":"Groll","year":"2000","journal-title":"J Infect Dis"},{"key":"2019071816003186200_dkx447-B88","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2019071816003186200_dkx447-B89","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40262-014-0139-0","article-title":"Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications","volume":"53","author":"Stockmann","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"2019071816003186200_dkx447-B90","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00228-014-1733-7","article-title":"GFR may not accurately predict aspects of proximal tubule drug handling","volume":"70","author":"Putt","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"2019071816003186200_dkx447-B91","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ndt\/gfi284","article-title":"Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg","volume":"21","author":"Bergner","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2019071816003186200_dkx447-B92","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5414\/CN108824","article-title":"Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach","volume":"86","author":"Gharibian","year":"2016","journal-title":"Clin Nephrol"},{"key":"2019071816003186200_dkx447-B93","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijantimicag.2015.02.017","article-title":"Influence of sustained low-efficiency diafiltration (SLED\u2013f) on interstitial fluid concentrations of fluconazole in a critically ill patient: use of microdialysis","volume":"46","author":"Sinnollareddy","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2019071816003186200_dkx447-B94","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijantimicag.2014.08.013","article-title":"Pharmacokinetics of fluconazole in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration","volume":"45","author":"Sinnollareddy","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2019071816003186200_dkx447-B95","doi-asserted-by":"crossref","first-page":"32.","DOI":"10.1186\/s13054-015-0753-8","article-title":"Evaluation of sulfobutylether-\u03b2-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy","volume":"19","author":"Kiser","year":"2015","journal-title":"Crit Care"},{"key":"2019071816003186200_dkx447-B96","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/tcrm.2007.3.1.71","article-title":"Comparison of echinocandin antifungals","volume":"3","author":"Eschenauer","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"2019071816003186200_dkx447-B97","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1093\/jac\/dkt542","article-title":"Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration","volume":"69","author":"Aguilar","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2019071816003186200_dkx447-B98","article-title":"Caspofungin population pharmacokinetics in critically ill patients undergoing continuous veno-venous haemofiltration or haemodiafiltration","author":"Roger","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2019071816003186200_dkx447-B99","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1128\/AAC.00335-13","article-title":"Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy","volume":"57","author":"Weiler","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B100","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1086\/444500","article-title":"Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy","volume":"41","author":"Trotman","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2019071816003186200_dkx447-B101","first-page":"927496.","article-title":"Flucytosine pharmacokinetics in a critically ill patient receiving continuous renal replacement therapy","volume":"2015","author":"Kunka","year":"2015","journal-title":"Case Rep Crit Care"},{"key":"2019071816003186200_dkx447-B102","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/clinids\/18.3.324","article-title":"Pharmacological, toxicologic, and microbiological considerations in the choice of initial antibiotic therapy for serious infections in patients with cirrhosis of the liver","volume":"18","author":"Westphal","year":"1994","journal-title":"Clin Infect Dis"},{"key":"2019071816003186200_dkx447-B103","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12281-010-0015-9","article-title":"Antifungal dose adjustment in renal and hepatic dysfunction: pharmacokinetic and pharmacodynamic considerations","volume":"4","author":"Cota","year":"2010","journal-title":"Curr Fungal Infect Reports"},{"key":"2019071816003186200_dkx447-B104","author":"European Medicines Agency"},{"key":"2019071816003186200_dkx447-B105","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1093\/jac\/dkv173","article-title":"Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis","volume":"70","author":"Grau","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2019071816003186200_dkx447-B106","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40262-015-0347-2","article-title":"Dose reduction of caspofungin in intensive care unit patients with Child Pugh B will result in suboptimal exposure","volume":"55","author":"Martial","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2019071816003186200_dkx447-B107","doi-asserted-by":"crossref","first-page":"741 e9","DOI":"10.1016\/j.jcrc.2012.02.013","article-title":"Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation","volume":"27","author":"Shekar","year":"2012","journal-title":"J Crit Care"},{"key":"2019071816003186200_dkx447-B108","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s00134-007-0606-2","article-title":"Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment","volume":"33","author":"Mehta","year":"2007","journal-title":"Intensive Care Med"},{"key":"2019071816003186200_dkx447-B109","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/jac\/dkp026","article-title":"Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation","volume":"63","author":"Spriet","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2019071816003186200_dkx447-B110","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/INF.0b013e31825d3091","article-title":"Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation","volume":"31","author":"Watt","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"2019071816003186200_dkx447-B111","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1128\/AAC.00102-15","article-title":"Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive candidiasis in children supported with extracorporeal membrane oxygenation","volume":"59","author":"Watt","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B112","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1128\/AAC.01088-16","article-title":"Effect of obesity on the population pharmacokinetics of fluconazole in critically ill patients","volume":"60","author":"Alobaid","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B113","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/phar.1156","article-title":"Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review","volume":"33","author":"Davies-Vorbrodt","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2019071816003186200_dkx447-B114","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1002\/phar.1192","article-title":"Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype","volume":"33","author":"Moriyama","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2019071816003186200_dkx447-B115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1586\/14787210.2016.1128822","article-title":"Dosing of antifungal agents in obese people","volume":"14","author":"Payne","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2019071816003186200_dkx447-B116","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal amphotericin B (AmBisome\u00ae): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"key":"2019071816003186200_dkx447-B117","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jac\/dkm125","article-title":"Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit","volume":"60","author":"Nguyen","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2019071816003186200_dkx447-B118","doi-asserted-by":"crossref","first-page":"83.","DOI":"10.1007\/s12281-011-0049-7","article-title":"Antifungal dosing in obesity: a review of the literature","volume":"5","author":"Amsden","year":"2011","journal-title":"Curr Fungal Infect Rep"},{"key":"2019071816003186200_dkx447-B119","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1128\/AAC.05193-11","article-title":"Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people","volume":"55","author":"Hall","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B120","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/cpt.38","article-title":"In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos","volume":"97","author":"Pasipanodya","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"2019071816003186200_dkx447-B121","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s40262-016-0401-8","article-title":"Does weight impact anidulafungin pharmacokinetics?","volume":"55","author":"Lempers","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2019071816003186200_dkx447-B122","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1128\/AAC.42.6.1512","article-title":"Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans","volume":"42","author":"Louie","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B123","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1128\/AAC.00398-07","article-title":"Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing","volume":"51","author":"Hope","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071816003186200_dkx447-B124","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/suppl_1\/i33\/23002632\/dkx447.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T07:05:19Z","timestamp":1659855919000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/suppl_1\/i33\/4769702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":124,"journal-issue":{"issue":"suppl_1","published-online":{"date-parts":[[2018,1,3]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx447","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2018,1,1]]}}}